Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.68 |
| ▸ | CSF1R | P07333 | 3/20 | 0.61 |
| ▸ | KDR | P35968 | 2/20 | 0.60 |
| ▸ | TEK | Q02763 | 1/20 | 0.60 |
| ▸ | KIT | P10721 | 4/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884314 | 0.92 | BRAF (0.68) | BRAFCSF1RKDRTEKKIT | |
| SCHEMBL15976959 | 0.90 | BRAF (0.58) | BRAFCSF1RKDRTEKKIT | |
| SCHEMBL4631343 | 0.88 | BRAF (0.58) | BRAFRAF1 | |
| SCHEMBL30899721 | 0.85 | ABL1 (0.67) | BRAFCSF1RKDRTEKKIT | |
| SCHEMBL2941693 | 0.85 | ABL1 (0.67) | BRAFCSF1RKDRTEKKIT | |
| SCHEMBL4879216 | 0.83 | ABL1 (0.61) | BRAFCSF1RKDRTEKKIT | |
| SCHEMBL27708222 | 0.82 | PIKFYVE (0.55) | BRAFCSF1RTEKABL1PIKFYVE | |
| SCHEMBL4878345 | 0.81 | RAF1 (0.53) | BRAFRAF1 | |
| SCHEMBL13198172 | 0.81 | BRAF (0.74) | BRAFCSF1RKDRTEKKIT | |
| SCHEMBL1408815 | 0.80 | ABL1 (0.77) | BRAFCSF1RKDRKITABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146570-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | claimed |
| EP-1924573-A1 | B-RAF INHIBITORS | AstraZeneca AB (SE) | 2008-05-28 | — | — | EP | claimed |
| WO-2006079791-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146570-A1 | Chemical Compounds | BRAF, RAF1, NRAS | BRAF 1/4885CSF1R 1706/4885KDR 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.